Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

INVENTOR PHARMA PVT LTD

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000866 76 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx76product presentations
G31generic molecules
DF7dosage-form groups
TA9therapeutic areas
PKR76current price records
REG60registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage91%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixINVENTOR PHARMA PVT LTDShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/inventor-pharma-pvt-ltdGenerated 10 Aug 2026Anti-infectives44 · 58%Gastrointestinal & hepatology7 · 9%Pain & musculoskeletal7 · 9%Endocrine & metabolic6 · 8%Vitamins, minerals & nutrition5 · 7%Anesthesia & critical care3 · 4%Oncology & immunology2 · 3%Other therapeutic areas2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioINVENTOR PHARMA PVT LTDDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/inventor-pharma-pvt-ltdGenerated 10 Aug 202676presentationsInjection25 · 33%Tablet25 · 33%Capsule11 · 14%Suspension10 · 13%Infusion2 · 3%Syrup2 · 3%Other forms1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionINVENTOR PHARMA PVT LTDCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/inventor-pharma-pvt-ltdGenerated 10 Aug 202669comparable productsBelow market median56 · 81%Near market median11 · 16%Above market median2 · 3%Company median price position-15.1%Lowest-price equivalents6Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsINVENTOR PHARMA PVT LTDCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/inventor-pharma-pvt-ltdGenerated 10 Aug 2026Mediate Pharmaceutical Pvt Ltd27 shared87% overlapM/s. Genix Pharma (Pvt) Ltd.26 shared84% overlapMacter International Limited25 shared81% overlapZafa Pharmaceutical Laboratories (P…25 shared81% overlapSemos Pharmaceuticals PVT LTD25 shared81% overlapPharmasol (Pvt) Ltd.24 shared77% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives44 products · 58%
Gastrointestinal & hepatology7 products · 9%
Pain & musculoskeletal7 products · 9%
Endocrine & metabolic6 products · 8%
Vitamins, minerals & nutrition5 products · 7%
Anesthesia & critical care3 products · 4%
Oncology & immunology2 products · 3%
Hematology & thrombosis1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins17 products · 22%
Fluoroquinolone antibacterials7 products · 9%
Analgesics / NSAIDs7 products · 9%
Antidiabetic medicines6 products · 8%
Macrolide antibacterials5 products · 7%
Vitamins / minerals / hematinics5 products · 7%
Antimalarials5 products · 7%
Proton pump inhibitors4 products · 5%
Formulation footprint

Dosage forms

Injection25 products
Tablet25 products
Capsule11 products
Suspension10 products
Infusion2 products
Syrup2 products
Drops1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 VENTZONCeftriaxone 6presentations 1000 MG, 1000 mg, 250 MG, 500 MG · Injection #2 PARAPALSParacetamol 5presentations 120 mg/5 mL, 120 MG/5 mL, 250 mg/5 mL, 250 MG/5 mL · Suspension #3 INTEKCefotaxime 4presentations 1 G, 250 MG, 500 MG · Injection #4 INVENZOLOmeprazole 4presentations 20 MG, 20 mg, 40 mg · Capsule #5 INDEONOndansetron 3presentations 8 mg, 8 mg/4 mL · Tablet, Injection #6 INLAXINCephalexin 3presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL · Suspension, Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median5681% of comparable products
Near market median11within ±5% of median
Above market median23% of comparable products
Lowest-price equivalents6ties included
Company median price position -15.1% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
LIDOCAINE 1 %Lidocaine · Injection · 2MLX1’S PKR 1.52/mL-51.4% vs market median Xotrz 100 mgItraconazole · Capsule · 1x4's PKR 75.00/capsule-47.8% vs market median PARAPALS 250 MG/5 mLParacetamol · Suspension · 90ML PKR 1.03/mL-31.6% vs market median PARAPALS 250 mg/5 mLParacetamol · Suspension · 120ML PKR 1.03/mL-31.6% vs market median IN-D3 5 MG/mLCholecalciferol · Injection · 5’S PKR 150.64/vial/unit-30.9% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 27shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 26shared generics Macter International Limited248 products · 91 generics 25shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 25shared generics Semos Pharmaceuticals PVT LTD103 products · 45 generics 25shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 24shared generics
Regulatory & price activity

Observed database signals

Registration numbers60
Price-history records93
Products with price history14
Source records with multiple versions1
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

7 results
Intelligence filter: Therapeutic areaAnti-infectives Drug classFluoroquinolone antibacterials Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
INCIP Ciprofloxacin 200 mg/100 mL IV infusion 100ML 088363 PKR 161.29 PKR 1.61/mL 27% below median
INMEX Moxifloxacin 400 MG Tablet 5'S 110360 PKR 721.19 PKR 144.24/tablet 20% below median
LEVOIN Levofloxacin 250 mg Tablet 10’S 086490 PKR 403.22 PKR 40.32/tablet 15% below median
LEVOIN Levofloxacin 500 mg Tablet 10’S 086489 PKR 670.95 PKR 67.10/tablet 15% below median
VORCIN Ciprofloxacin 250 mg Tablet 10’S 086491 PKR 209.68 PKR 20.97/tablet 17% below median
VORCIN Ciprofloxacin 750 mg Tablet 10’S 086493 PKR 370.97 PKR 37.10/tablet 6% below median
VORCIN Ciprofloxacin 500 mg Tablet 10’S 086492 PKR 346.77 PKR 34.68/tablet 17% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.